Compare ADEA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADEA | WGS |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2020 | 2020 |
| Metric | ADEA | WGS |
|---|---|---|
| Price | $13.01 | $45.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $38.25 | ★ $82.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ 73.68 | 62.37 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $443,386,000.00 | $427,539,000.00 |
| Revenue This Year | N/A | $11.40 |
| Revenue Next Year | $8.99 | $19.61 |
| P/E Ratio | $39.05 | ★ N/A |
| Revenue Growth | 17.91 | ★ 39.97 |
| 52 Week Low | $11.93 | $32.21 |
| 52 Week High | $34.34 | $170.87 |
| Indicator | ADEA | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 24.07 | 33.81 |
| Support Level | N/A | $32.21 |
| Resistance Level | $26.48 | $72.65 |
| Average True Range (ATR) | 0.94 | 5.39 |
| MACD | -0.19 | -0.98 |
| Stochastic Oscillator | 0.70 | 4.82 |
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.